Journal ArticleDOI
Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited
Gustav Paumgartner,Ulrich Beuers +1 more
Reads0
Chats0
TLDR
Experimental evidence suggests three major mechanisms of action of UDCA, which may improve serum liver chemistries, delay disease progression to severe fibrosis or cirrhosis, and may prolong transplant‐free survival in primary biliary Cirrhosis and primary sclerosing cholangitis.About:
This article is published in Hepatology.The article was published on 2002-09-01. It has received 643 citations till now. The article focuses on the topics: Ursodeoxycholic acid & Bile acid.read more
Citations
More filters
Journal ArticleDOI
Enterohepatic Bile Salt Transporters in Normal Physiology and Liver Disease
TL;DR: A key regulator of hepatocellular bile salt homeostasis is the bile acid receptor/farnesoid X receptor FXR, which activates transcription of the BSEP and OATP8 genes and of the small heterodimer partner 1 (SHP) as mentioned in this paper.
Journal ArticleDOI
Bile-acid-induced cell injury and protection
Maria J. Perez,Oscar Briz +1 more
TL;DR: The major beneficial effects of treatment with ursodeoxycholic acid are protection against cytotoxicity due to more toxic BAs; the stimulation of hepatobiliary secretion; antioxidant activity, due in part to an enhancement in glutathione levels; and the inhibition of liver cell apoptosis.
Journal ArticleDOI
Herb-drug interactions: a literature review.
Zeping Hu,Xiaoxia Yang,Paul C. Ho,Sui Yung Chan,Paul Wan Sia Heng,Eli Chan,Wei Duan,Hwee-Ling Koh,Shu-Feng Zhou +8 more
TL;DR: An extensive review of the literature identified reported herb-drug interactions with clinical significance, although the underlying mechanisms for the altered drug effects and/or concentrations by concomitant herbal medicines are yet to be determined.
Journal ArticleDOI
Intrahepatic cholestasis of pregnancy
Thomas Pusl,Ulrich Beuers +1 more
TL;DR: The hydrophilic bile acid ursodeoxycholic acid (10–20 mg/kg/d) is today regarded as the first line treatment for intrahepatic cholestasis of pregnancy.
Journal ArticleDOI
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
Stefano Fiorucci,Elisabetta Antonelli,Giovanni Rizzo,Barbara Renga,Andrea Mencarelli,Luisa Riccardi,Stefano Orlandi,Roberto Pellicciari,Antonio Morelli +8 more
TL;DR: It is established that FXR ligands might represent a novel therapeutic option to treat liver fibrosis and that SHP binds JunD and inhibits DNA binding of adaptor protein (AP)-1 induced by thrombin.
References
More filters
Journal ArticleDOI
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
TL;DR: Ursodiol is a safe and effective treatment for primary biliary cirrhosis and follow-up analysis of 95 liver-biopsy specimens showed a significant improvement in the mean histologic score and in all the characteristic histologic features except fibrosis only in the group given ursodiol.
Journal ArticleDOI
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
TL;DR: Survival free of liver transplantation was significantly improved in the patients treated with UDCA compared with the patients originally assigned to placebo, and long-term UDCA therapy improves survival free of Liver transplantation in patients with moderate or severe disease.
Journal ArticleDOI
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
William A. Faubion,M. Eugenia Guicciardi,Hideyuki Miyoshi,Steven F. Bronk,Patricia J. Roberts,Phyllis A. Svingen,Scott H. Kaufmann,Gregory J. Gores +7 more
TL;DR: Data suggest that GCDC-induced hepatocyte apoptosis involves ligand-independent oligomerization of Fas, recruitment of FADD, activation of caspase 8, and subsequent activation of effector proteases, including downstream caspases and cathepsin B.
Journal ArticleDOI
Ursodiol for Primary Sclerosing Cholangitis
TL;DR: Ursodiol (ursodeoxycholic acid) benefits patients with primary biliary cirrhosis, another cholestatic liver disease, and well-documented primary sclerosing cholangitis in a randomized, double-blind study comparing ursodiol with placebo.
Journal ArticleDOI
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Keith D. Lindor,E. Rolland Dickson,William P. Baldus,Roberta A. Jorgensen,Jurgen Ludwig,Paul A. Murtaugh,Jay M. Harrison,Russell H. Wiesner,Monte L. Anderson,Stephen Lange,Gene LeSage,Steven S. Rossi,Alan F. Hofmann +12 more
TL;DR: UDCA was extraordinarily safe and well tolerated, and its use was associated with delayed progression of the disease as defined in this study, however, the lack of effects on symptoms, histology, and the need for liver transplantation or survival indicate that further evaluation is necessary.
Related Papers (5)
High Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis
Keith D. Lindor,Kris V. Kowdley,Velimir A. Luketic,M. Edwyn Harrison,Timothy M. McCashland,Alex S. Befeler,Denise M. Harnois,Roberta A. Jorgensen,Jan Petz,Jill C. Keach,Jody Mooney,Carol Sargeant,Tamara Bernard,Debra King,Ellen Miceli,Jeff Schmoll,Tanya L. Hoskin,Prabin Thapa,Felicity Enders +18 more